Suchergebnisse - "Buti, Maria"

PubPharm (36)

1

Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort

enthalten in: Hepatology international | 2022

von Hsu, Y. | Jun, D. | Peng, C. | +43

2

An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B

enthalten in: Journal of hepatology | 2022

von Kim, H. | Lampertico, P. | Nam, J. | +33

3

Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B

enthalten in: The Journal of infectious diseases | 2021

von Hsu, Y. | Yeh, M. | Wong, G. | +27

4

Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

enthalten in: Journal of hepatology | 2020

von Papatheodoridis, G. | Dalekos, G. | Idilman, R. | +21

CommentIn: J Hepatol. 2021 Jan;74(1):246-247. - PMID 32988659

5

Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2020

von Roade, L. | Loglio, A. | Borghi, M. | +9

6

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment : results from a 7-year, multicentre retrospective cohort study

enthalten in: Alimentary pharmacology & therapeutics | 2020

von Lampertico, P. | Berg, T. | Buti, M. | +66

CommentIn: Aliment Pharmacol Ther. 2020 Sep;52(5):889-890. - PMID 32852818

7

Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B

enthalten in: Journal of hepatology | 2020

von Papatheodoridis, G. | Sypsa, V. | Dalekos, G. | +23

CommentIn: J Hepatol. 2020 Jul;73(1):223-224. - PMID 32229038

8

Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

enthalten in: Journal of hepatology | 2018

von Papatheodoridis, G. | Sypsa, V. | Dalekos, G. | +24

9

Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2018

von Buti, M. | Riveiro-Barciela, M. | Esteban, R.

10

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

enthalten in: Hepatology (Baltimore, Md.) | 2017

von Papatheodoridis, G. | Idilman, R. | Dalekos, G. | +24

CommentIn: Hepatobiliary Surg Nutr. 2018 Jun;7(3):212-213. - PMID 30046577